Avidity Biosciences, Inc (RNAM) Stock
RNAM is no longer traded. Avidity Biosciences was acquired by Novartis (NVS) in February 2026.
Each RNAM share was exchanged for $72.00 in cash, plus shares of a spun-off company (SpinCo). Prices on this page are historical; the last trade was February 25, 2026 at $71.34.
See Novartis (NVS) stock →Avidity Biosciences stock price history
RNAM final trading statistics
- Final close
- $71.34
- Final trading day
- Feb 25, 2026
- Market cap at delisting
- $11.02B
- Shares outstanding
- 154.48M
- Final 52-week range
- $21.51 – $73.06
- Avg. volume (final 3 mo.)
- 2,103,574
- All-time high (split-adj.)
- $72.93 · Feb 2026
- All-time low (split-adj.)
- $4.87 · Oct 2023
- Return since IPO
- +150.3%
- Beta
- 0.93
- Book value / share
- $11.17
- Price / book
- 6.39
Avidity Biosciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $18.75M | -$684.6M | -$4.97 |
| FY2024 | $10.90M | -$322.3M | — |
| FY2023 | $9.56M | -$212.2M | — |
| FY2022 | $9.22M | -$174.0M | — |
| FY2021 | $9.33M | -$118.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. As of February 27, 2026, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG.
Avidity Biosciences stock FAQ
What happened to Avidity Biosciences stock?
Avidity Biosciences was acquired by Novartis (NVS) in February 2026. Shareholders received $72.00 in cash, plus shares of a spun-off company (SpinCo) for each share. RNAM stock stopped trading on the Nasdaq, with a final close of $71.34 on February 25, 2026.
What did Avidity Biosciences shareholders receive?
Each RNAM share was converted into $72.00 in cash, plus shares of a spun-off company (SpinCo). The deal was valued at about $12 billion.
Is RNAM stock still trading?
No. RNAM was delisted from the Nasdaq in February 2026 and no longer trades on a U.S. exchange. Former Avidity Biosciences shareholders received Novartis (NVS) shares.
What was the last price of RNAM stock?
RNAM closed at $71.34 on its final trading day, February 25, 2026, for a market value of about $11.02B.
What were Avidity Biosciences's revenue and earnings in its last full fiscal year?
Avidity Biosciences reported revenue of $18.75M and net income of -$684.6M in fiscal 2025, its last full year as a public company.
When did Avidity Biosciences go public?
Avidity Biosciences, Inc stock began trading on June 28, 2013.